123-Iodine MIBG in the Assessment of Sympathetic Denervation in Ogilvie's Syndrome

Abstract

123-Iodine metaiodobenzylguanidine (I-123 MIBG) imaging is frequently used in the assessment of sympathetic innervation and autonomic dysfunction in patients with cardiac failure, neurodegenerative Parkinson's syndrome, multiple system atrophy, myotonic dystrophy, and diabetic mellitus. The etiology of pseudo-obstruction remains unknown with likely imbalance between sympathetic and parasympathetic innervation proposed as a hypothesis. We present a case demonstrating the utility of I-123 MIBG scintigraphy for evaluating a case of pseudo-obstruction requiring frequent hospitalization due to progressive complex autoimmune neurological disorder.

Keywords

I-123 MIBG - autonomic neuropathy - Ogilvie's syndrome - pseudo-obstruction - sympathetic dysfunction

Note

The manuscript has been read and approved by the author that the requirements for authorship as stated earlier in this document have been met, and that author believes that the manuscript represents honest work, if that information is not provided in another form.

Publication History

Article published online:
09 September 2022

• Reference

• 1 Chung EJ, Lee WY, Yoon WT, Kim BJ, Lee GH. MIBG scintigraphy for differentiating Parkinson's disease with autonomic dysfunction from Parkinsonism-predominant multiple system atrophy. Mov Disord 2009; 24 (11) 1650-1655
• 2 Harnsberger CR. Acute colonic pseudo-obstruction (Ogilvie's syndrome). Semin Colon Rectal Surg 2019; 30 (03) 100690
• 3 Wells CI, O'Grady G, Bissett IP. Acute colonic pseudo-obstruction: a systematic review of aetiology and mechanisms. World J Gastroenterol 2017; 23 (30) 5634-5644
• 4 Osinga TE, Kerstens MN, van der Klauw MM. et al. Intestinal pseudo-obstruction as a complication of paragangliomas: case report and literature review. Neth J Med 2013; 71 (10) 512-517
• 5 Flotats A, Carrió I, Agostini D. et al; EANM Cardiovascular Committee, European Council of Nuclear Cardiology. Proposal for standardization of 123I-metaiodobenzylguanidine (MIBG) cardiac sympathetic imaging by the EANM Cardiovascular Committee and the European Council of Nuclear Cardiology. Eur J Nucl Med Mol Imaging 2010; 37 (09) 1802-1812
• 6 Sisson JC, Shapiro B, Meyers L. et al. Metaiodobenzylguanidine to map scintigraphically the adrenergic nervous system in man. J Nucl Med 1987; 28 (10) 1625-1636
• 7 Wakabayashi T, Nakata T, Hashimoto A. et al. Assessment of underlying etiology and cardiac sympathetic innervation to identify patients at high risk of cardiac death. J Nucl Med 2001; 42 (12) 1757-1767
• 8 Genovese EA, Mallardo V, Cipullo S. et al. [Cardiac sympathetic innervation imaging with myocardial MIBG scintigraphy]. Recenti Prog Med 2013; 104 (7-8): 356-360
• 9 Ichikawa Y, Takeda K, Murashima S. et al. Increased myocardial uptake of iodine-123 metaiodobenzylguanidine on delayed images, compared with early images, in patients with multiple system atrophy. Clin Nucl Med 2003; 28 (11) 890-892
• 10 Landesmann MC, da Fonseca LM, de B Pereira B. et al. Iodine-123 metaiodobenzylguanidine cardiac imaging as a method to detect early sympathetic neuronal dysfunction in chagasic patients with normal or borderline electrocardiogram and preserved ventricular function. Clin Nucl Med 2011; 36 (09) 757-761